Celgene Announces Discontinue Phase III MAINSAIL Trial; ICON seeks First FDA Approval of Traditional Chinese Medicine Print E-mail
By Staff and Wire Reports   
Tuesday, 22 November 2011 19:46
Below is a look at some of the headlines for companies that made news in the healthcare sector on November 22, 2011.

Celgene Corporation (NASDAQ:CELG) announced based on the recommendation from the Data Monitoring Committee (DMC) it will discontinue its pivotal double-blinded Phase III MAINSAIL trial that was designed to evaluate the efficacy and safety of docetaxel and prednisone with or without lenalidomide in patients with castrate-resistant prostate cancer (CRPC).

It was determined that the combination of docetaxel and prednisone plus lenalidomide would not demonstrate a statistically treatment effect against the primary endpoint of overall survival versus docetaxel and prednisone plus placebo.

Celgene drops 1.8% AH after stating it will discontinue Phase III trials for evaluating the use of its Revlimid drug to help treat prostate cancer.


ICON plc, (NASDAQ: ICLR), $15.48 0.25 (1.64%), announced it has been selected by Tasly Pharmaceuticals for the company's global Phase III T89 trial. T89, also known as Dantonic pill, aims to become the first traditional Chinese medicine to receive FDA approval in the United States.

Also Tuesday:

Accelr8 Technology Corporation (NYSE Amex: AXK) announced that it successfully completed two technical feasibility studies for test methods that expand its BACcel™ rapid diagnostic test library and automation capabilities.

Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that Ron Cohen, M.D., President & CEO, will present at the Piper Jaffray 23rd Annual Healthcare Conference on Tuesday, November 29, 2011 at 11:00 a.m. Eastern Time at the Plaza Hotel in New York, NY.

Amarantus BioSciences, Inc. (OTCBB:AMBS)
, a biotechnology company developing MANF, a first-in-class disease–modifying therapeutic protein and Banyan Biomarkers, the leader in developing in vitro diagnostic products to detect traumatic brain injury (TBI), today announced a collaboration agreement to evaluate MANF’s potential as a disease-modifying agent for the treatment of TBI.

Astex Pharmaceuticals, Inc. (NASDAQ: ASTX), a pharmaceutical company dedicated to the discovery and development of novel therapeutics, today announced that James S.J. Manuso, Ph.D., chairman and chief executive officer, and Mohammad Azab, M.D., chief medical officer, will present at the 23rd Annual Piper Jaffray Health Care Conference on Tuesday, November 29th in New York.

AtheroNova Inc. (OTCBB: AHRO) ("AtheroNova"), a biotech company focused on the research and development of compounds to regress atherosclerotic plaque, announced the recent presentation by Diana Shih, Ph.D., Associate Professor of Medicine, Division of Cardiology at the David Geffen School of Medicine at UCLA, at the 2011 American Heart Association (AHA) Scientific Sessions in Orlando, Florida.

BioLineRx (NASDAQ:BLRX) (TASE:BLRX), a biopharmaceutical development company, announced today that it has received approval from the Indian regulatory authorities and the Indian local ethics committees to commence the Phase II/III CLARITY clinical trial of BL-1020, a first in class, orally available, GABA-enhanced antipsychotic for the treatment of schizophrenia.

Bio-Reference Laboratories, Inc. (NASDAQ: BRLI)
announced today that it has entered into a purchasing agreement with a McKesson Specialty Health group purchasing organization (GPO), the Onmark GPO.

Biovest International, Inc. (OTCQB:BVTI), a majority-owned subsidiary of Accentia Biopharmaceuticals, Inc. (OTCQB:ABPI), today reported that its correspondence to the Editor was published in the November 2011 issue of the Journal of Clinical Oncology (JCO), defining the role of BiovaxID® as a safe and effective personalized cancer vaccine for the treatment of certain B-cell subtypes of non-Hodgkin’s lymphoma.

CONMED Corporation (NASDAQ: CNMD), a medical technology company specializing in medical devices for surgical and patient monitoring markets, announced today that the Company will participate in the 23rd Annual Piper Jaffray Health Care Conference, on Wednesday, November 30, 2011 at 2:30 PM Eastern time.

Exelixis, Inc. (NASDAQ:EXEL) today announced that Michael M. Morrissey, Ph.D., the company’s president and chief executive officer, will present at the Piper Jaffray Health Care Conference at 3:30 p.m. EST / 12:30 p.m. PST on Tuesday, November 29, 2011 in New York.

IsoRay, Inc. (Amex: ISR) announced today it has received final approval from the State of Washington Department of Health to manufacture itsGliaSite® radiation therapy system, a balloon catheter device used in the treatment of brain cancer.

InVivo Therapeutics Holdings Corp. (OTCBB: NVIV), a developer of groundbreaking technologies for the treatment of spinal cord injuries (SCI), today announced CEO Frank Reynolds will present InVivo’s most recent breakthroughs and provide a business update to potential investors during the 23rd Annual Piper Jaffray Health Care Conference.

Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) announced today that it has commenced its previously announced rights offering pursuant to an effective registration statement and today began mailing a prospectus and other rights offering materials to its stockholders.

MabCure, Inc. (OTCBB: MBCI)
, a leading developer of antibody-based diagnostics and treatments for ovarian and prostate cancer, today announced that it has signed a license agreement with Biotech Investment Corp. (“Biotech”), a Nevada-based biotechnology investment company.

MELA Sciences, Inc. (NASDAQ: MELA) announced today that Joseph V. Gulfo, MD, President and CEO, will present at the Piper Jaffray 23rd Annual Healthcare Conference taking place November 29-30 at The New York Palace Hotel.

mPhase Technologies, Inc. (OTCBB: XDSL) has developed a technology that exploits the phenomenon of electrowetting or the ability to electronically manipulate the way liquids behave when in contact with a solid or porous surface.

Nuvilex, Inc. (OTCQB:NVLX) announced today testing confirmed that through use of live cell encapsulation technology, two major obstacles facing the vast and broad applications of live stem cell use have been overcome.

Osiris Therapeutics, Inc. (NASDAQ: OSIR), the leading stem cell company focused on developing and marketing products to treat medical conditions in inflammatory and cardiovascular disease areas and wound healing, announced today that C. Randal Mills, Ph.D., President and Chief Executive Officer, is scheduled to present at the 23rd Annual Piper Jaffray Healthcare Conference on Tuesday, November 29, 2011 at 8:00 a.m. ET in New York City.

PAREXEL International (NASDAQ: PRXL), a leading global biopharmaceutical services provider, today announced that it has enhanced its central nervous system (CNS) capabilities for clinical development through the implementation of functional magnetic resonance imaging (fMRI) technology in its Early Phase units.

PDI, Inc. (Nasdaq: PDII) today announced that Nancy Lurker, the company's chief executive officer, is scheduled to present at the Piper Jaffray 23rd Annual Health Care Conference at 10:10 am ET on November 30, 2011 at The New York Palace Hotel in New York City.

Pfizer Inc. (NYSE: PFE) and Excaliard Pharmaceuticals, Inc. announced today that they have entered into a definitive agreement under which Pfizer will acquire Excaliard, a privately owned biopharmaceutical company focused on developing novel drugs for the treatment of skin fibrosis, more commonly referred to as skin scarring.

pSivida Corp. (NASDAQ:PSDV; ASX:PVA), a leader in developing sustained release, drug delivery products for treatment of back-of-the-eye diseases, today announced that it has signed a funded technology evaluation agreement with a leading global pharmaceutical company to evaluate pSivida’s bioerodible Durasert™ drug delivery technology in ophthalmology.

Sequenom, Inc. (NASDAQ: SQNM), a life sciences company providing innovative genetic analysis solutions, today announced the Company's participation at the 23rd Annual Piper Jaffray Healthcare Conference at the Palace Hotel in New York City November 29-30, 2011.

Stellar Biotechnologies, Inc. "Stellar"(TSX-V: KLH) (PINKSHEETS: SBOTF)
is pleased to report two recent news stories on the company, by the National Cancer Institute (NCI) and in Popular Science magazine.

ZIOPHARM Oncology, Inc. (Nasdaq: ZIOP)
announced today that Jonathan Lewis, M.D., Ph.D., Chief Executive Officer, will present at the 23rd Annual Piper Jaffray Health Care Conference on Tuesday, November 29, 2011, at 4:00 pm Eastern Time, at The New York Palace Hotel in New York City.

"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus